Dr. Arun K. Shukla is a world leader in the field of GPCR biology and he is currently a Professor in the Department of Biological Sciences and Bioengineering at the Institute of Technology, Kanpur in India. Dr. Shukla’s research program is focused on understanding the structure, function and regulation of G protein-coupled receptors with a long-term of designing novel therapeutics with minimized side-effects.

• 1. HERs Transregulation in Cancer Progression: From Discovery to 2020 and BeyondRakesh Kumar2. RTKs in Cancer BiologyPaul Fisher3. Advances in EGFR Biochemistry and BiologyYosef Yarden4. Mouse Models of RTKs/HERs: Lessons and Implications to Biology and TherapyWilliam Joseph Muller5. MET Receptor in Oncology: From Biomarker to Therapeutic TargetRavi Salgia6. RTKs in Pathobiology of Head & Neck CancerRadhakrishna Pillai7. HER2 or Nuclear HER/RTK in CancerMien-Chie Hung8. FLT3 in Hematopietic Malignancies: From Pathobiology to TherapeuticsPremkumar Reddy9. Advances in IGF1R Biology and –directed Cancer TherapeuticsDouglas Yee10. Advances in Bcr-Abl in Cancer Therapy and BiologyNandini Verma11. EphRs in Cancer Development and ProgressionRenata Pasqualini12. RTK-directed Clinical Advances: Trials and TreatmentsMasakazu Toi

Dr. Arun K. Shukla is a world leader in the field of GPCR biology and he is currently a Professor in the Department of Biological Sciences and Bioengineering at the Institute of Technology, Kanpur in India. Dr. Shukla’s research program is focused on understanding the structure, function and regulation of G protein-coupled receptors with a long-term of designing novel therapeutics with minimized side-effects.

• 1. HERs Transregulation in Cancer Progression: From Discovery to 2020 and BeyondRakesh Kumar2. RTKs in Cancer BiologyPaul Fisher3. Advances in EGFR Biochemistry and BiologyYosef Yarden4. Mouse Models of RTKs/HERs: Lessons and Implications to Biology and TherapyWilliam Joseph Muller5. MET Receptor in Oncology: From Biomarker to Therapeutic TargetRavi Salgia6. RTKs in Pathobiology of Head & Neck CancerRadhakrishna Pillai7. HER2 or Nuclear HER/RTK in CancerMien-Chie Hung8. FLT3 in Hematopietic Malignancies: From Pathobiology to TherapeuticsPremkumar Reddy9. Advances in IGF1R Biology and –directed Cancer TherapeuticsDouglas Yee10. Advances in Bcr-Abl in Cancer Therapy and BiologyNandini Verma11. EphRs in Cancer Development and ProgressionRenata Pasqualini12. RTK-directed Clinical Advances: Trials and TreatmentsMasakazu Toi

Dr. Arun K. Shukla is a world leader in the field of GPCR biology and he is currently a Professor in the Department of Biological Sciences and Bioengineering at the Institute of Technology, Kanpur in India. Dr. Shukla’s research program is focused on understanding the structure, function and regulation of G protein-coupled receptors with a long-term of designing novel therapeutics with minimized side-effects.

• 1. HERs Transregulation in Cancer Progression: From Discovery to 2020 and BeyondRakesh Kumar2. RTKs in Cancer BiologyPaul Fisher3. Advances in EGFR Biochemistry and BiologyYosef Yarden4. Mouse Models of RTKs/HERs: Lessons and Implications to Biology and TherapyWilliam Joseph Muller5. MET Receptor in Oncology: From Biomarker to Therapeutic TargetRavi Salgia6. RTKs in Pathobiology of Head & Neck CancerRadhakrishna Pillai7. HER2 or Nuclear HER/RTK in CancerMien-Chie Hung8. FLT3 in Hematopietic Malignancies: From Pathobiology to TherapeuticsPremkumar Reddy9. Advances in IGF1R Biology and –directed Cancer TherapeuticsDouglas Yee10. Advances in Bcr-Abl in Cancer Therapy and BiologyNandini Verma11. EphRs in Cancer Development and ProgressionRenata Pasqualini12. RTK-directed Clinical Advances: Trials and TreatmentsMasakazu Toi